Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Training may have supported care outcome improvements In South Africa, where in 2014 an estimated 6,8 million people were living with HIV, and where an estimated […]
Using data on outcomes and impacts of tuberculosis across four countries with some of the highest rates of the disease, researchers from the U.S. Centers for […]
In the face of a proposal by the Trump administration to cut funding for the National Institutes of Health by nearly a quarter with an $8 […]
U.S. global health leadership more critical to security, stability and prosperity than ever, National Academy of Science report argues
As priorities shift under new administration, report makes case that foreign assistance in U.S. interests, but requires improved efficiencies, sustainability In a report written with an […]